Evaxion A/S (EVAX) Stock Price, News & Analysis

Company Overview

Evaxion A/S is a clinical‐stage biotechnology company focused on harnessing artificial intelligence to develop novel immunotherapies. Headquartered in Copenhagen, Denmark, the company leverages its proprietary AI‐powered platforms to design precision vaccines and therapeutic candidates targeting both oncology and infectious diseases. Evaxion’s approach integrates computational algorithms with advanced immunology to accelerate the discovery and optimization of immunogenic peptides capable of triggering robust immune responses.

The company’s core offering is its PIONEER™ drug discovery platform, which utilizes machine learning and deep sequencing data to predict and validate epitopes that can be formulated into vaccines or biologics. Evaxion has built a diverse pipeline of preclinical and clinical‐stage products, including personalized cancer vaccines aimed at neoantigens in solid tumors and preventive vaccines for emerging infectious threats. By combining in silico design with in vitro and in vivo validation, Evaxion seeks to reduce development timelines and increase the likelihood of clinical success.

Founded in 2017 as a spin‐out from Danish academic institutions, Evaxion has grown to serve a global market, collaborating with leading research centers and pharmaceutical partners in Europe and the United States. The company’s research programs encompass areas such as melanoma, non‐small cell lung cancer, and neglected tropical diseases. Over time, Evaxion has secured strategic alliances to advance its clinical trials and expand manufacturing capabilities, positioning itself as an innovator in the field of AI‐driven immunotherapy.

Evaxion’s leadership team combines expertise in computational biology, immuno‐oncology, and pharmaceutical development. The executive management and scientific advisory board include seasoned professionals with backgrounds in biostatistics, molecular immunology, and regulatory affairs. Under this multidisciplinary leadership, Evaxion continues to refine its AI platforms and drive multiple collaborative programs toward clinical milestones, aiming to deliver first‐in‐class therapeutics that address critical unmet needs in cancer and infectious disease treatment.

Key Stats

• Today's Range: $2.54 to $2.85
• 50-Day Range: $1.44 to $3.13
• 52-Week Range: $1.20 to $17.75
• Volume: 362,449 shs
• Average Volume: 620,782 shs
• Market Capitalization: $3.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Evaxion A/S Stock Analysis - MarketRank™

Evaxion A/S scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evaxion A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evaxion A/S has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Evaxion A/S are expected to decrease in the coming year, from ($0.15) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evaxion A/S is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evaxion A/S is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.00% of the float of Evaxion A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion A/S has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion A/S has recently decreased by 16.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evaxion A/S does not currently pay a dividend.

Dividend Growth

Evaxion A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.00% of the float of Evaxion A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion A/S has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion A/S has recently decreased by 16.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

Evaxion A/S has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Evaxion A/S this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for EVAX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evaxion A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.04% of the stock of Evaxion A/S is held by institutions.

EVAX Stock Analysis - Frequently Asked Questions

How have EVAX shares performed this year?

Evaxion A/S's stock was trading at $4.2270 at the beginning of 2025. Since then, EVAX shares have decreased by 37.1% and is now trading at $2.66.

How were Evaxion A/S's earnings last quarter?

Evaxion A/S - Sponsored ADR (NASDAQ:EVAX) issued its quarterly earnings results on Tuesday, May, 27th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.36. Evaxion A/S had a negative trailing twelve-month return on equity of 532.72% and a negative net margin of 316.03%.
Read the conference call transcript.

When did Evaxion A/S's stock split?

Evaxion A/S shares reverse split on Monday, January 13th 2025.The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Evaxion A/S IPO?

Evaxion A/S (EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

How do I buy shares of Evaxion A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evaxion A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML).

Company Calendar

• Last Earnings: 5/27/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVAX
• CIK: 1828253
• Web: www.evaxion-biotech.com
• Phone: 45-5353-1850
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Evaxion A/S: $10.00
• High Price Target: $14.00
• Low Price Target: $6.00
• Potential Upside/Downside: +275.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.57 million
• Net Margins: -316.03%
• Pretax Margin: -428.27%
• Return on Equity: -532.72%
• Return on Assets: -78.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.01
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: $3.34 million
• Price / Sales: 1.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.18) per share
• Price / Book: -2.25

Miscellaneous

• Outstanding Shares: 1,400,000
• Free Float: 819,000
• Market Cap: $3.72 million
• Optionable: No Data
• Beta: 0.12